Optimum Platelet Inhibition After Coronary Bypass Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2002-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the effect of different dosages of aspirin on platelet aggregation and to determine the possible mechanisms of aspirin resistance, we intend to compare the effects of low, medium dose aspirin with clopidogrel (an alternative antiplatelet agent) in patients after coronary artery bypass surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Aspirin and Plavix Following Coronary Artery Bypass Grafting

NCT01158703

Coronary Graft Patency

TERMINATED PHASE4

Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study

NCT00330772

Coronary Artery Disease Coronary Artery Bypass Grafting

COMPLETED PHASE3

Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery

NCT01466452

Coronary Arteriosclerosis

UNKNOWN PHASE2

Impact of Combination of Clopidogrel With Aspirin on Postoperative Bleeding in Coronary Surgical Patients

NCT01216150

Coronary Surgery Hemorrhage

COMPLETED

The Effects of Preoperative Aspirin on Graft Patency and Cardiac Events in Off-pump Coronary Artery Bypass

NCT01268917

Coronary Artery Disease Off-pump Coronary Artery Bypass Aspirin

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aspirin, Clopidogrel

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

We intend to invite patients aged 18 to 80 proceeding to primary elective coronary artery bypass surgery, able to give informed consent.

Exclusion Criteria

* patients who are have not stopped aspirin 7 days prior to surgery
* patients on concomitant NSAIDS
* patients with a previous history platelet disorders, splenectomy or haematological disorders
* patients with aspirin induced asthma
* patients with any contraindications to aspirin (GI bleed)
* patients who are on any medication that may result in a serious drug interaction with aspirin (warfarin)
* Women of childbearing potential
* Patients of less than 18 years
* If informed consent cannot be obtained
* If for any reason the consultant surgeon or anaesthetist deems it to be appropriate

• Concomitant procedures

* patients who receive platelet transfusion
* patients who receive NSAIDS
* requirement for intra aortic balloon pump support
* failure of extubation within 24 hours

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No